Botox cleared for third cosmetic indication in the USA

Dublin-incorporated Allergan says the US FDA has approved its application to add a third indication to the label for Botox Cosmetic (OnabotulinumtoxinA).

The cosmetic can now be marketed as a treatment for temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adults.

Botox is now indicated to treat forehead lines, crow's feet lines and glabellar lines. Botox is the only neurotoxin brand to receive approval of aesthetic indications beyond glabellar lines in the USA.